Ozempic Link to Rare Vision Loss Risk Confirmed in Study (1)

December 13, 2024, 4:12 PM UTC

Novo Nordisk A/S’s blockbuster shot Ozempic was linked to an increased risk of a rare form of vision loss in a study that backs up Harvard University research published earlier this year.

Diabetes patients who used Ozempic were more than twice as likely to be diagnosed with the rare condition, called NAION, than those who took another type of diabetes drug, according to a team of researchers who studied years of patient records from Denmark and Norway. The study wasn’t able to determine whether there was a similar impact among people taking Ozempic’s sister drug, Wegovy, for obesity.

The ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.